跳至主要内容
临床试验/NCT06305663
NCT06305663招募中不适用

A Multi-center, Randomized, Parallel, Bilateral, Investigator-masked Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

Bausch & Lomb Incorporated11 个研究点 分布在 1 个国家目标入组 418 人开始时间: 2024年3月29日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
418
试验地点
11
主要终点
Mean change from baseline in axial length.

研究概览

简要总结

A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

详细描述

A Multi-center, Randomized, Parallel, Bilateral, Investigator-masked study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Double (Participant, Outcomes Assessor)

盲法说明

The identity of the study eye will be masked to subjects, assessors, and other masked personnel while masking is maintained..

入排标准

年龄范围
8 Years 至 12 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Male or female aged 8 to 12 years plus 11 months old on the date the Informed Assent and Parental or Guardian Informed Consent are signed and have capacity to provide voluntary informed consent.
  • Subject must meet the following determined by cycloplegic subjective refraction in both eyes at screening:
  • Spherical Equivalent Refractive Error (SERE): between -0.75 D and -4.00 D, inclusive.
  • Astigmatism: ≤ -0.75 D. c. Anisometropia: < 1.00 D.
  • Subject must be myopic and require lens correction from -0.75 D to -4.00 D, at screening, in each eye.
  • Subject must have distance best-spectacle corrected visual acuity (BSCVA) by non-cycloplegic manifest refraction of +0.04 logMAR (20/20 Snellen equivalent) or better in each eye.
  • Subject and Parent or Guardian must be willing to participate in either the test or the comparator assignment.
  • Subject agrees to wear the assigned contact lenses for a minimum of 10 hours per day, at least 6 days per week, for the duration of the 24-month study.
  • Subject must have wearable and visually functioning eyeglasses.
  • Subject must be in good general health according to their and parent's or guardian's knowledge

排除标准

  • Subject has previously worn, or currently wears rigid gas permeable contact lenses, including orthokeratology lenses.
  • Current or prior use of bifocals, progressive addition lenses, multifocal soft contact lenses, atropine, pirenzepine or ANY other myopia control treatment.
  • Subject appears to exhibit poor personal hygiene (that in the Investigator's opinion might prevent safe contact lens wear).
  • Per oral inquiry from parents/guardian, the subject was born earlier than 30 weeks or weighed less than 1,500 g at birth.
  • Prior strabismus, intraocular, or refractive surgery.
  • Subject using any systemic or local eye medication that interfere with the wearing of corneal contact lenses, pupil size, adjustment or refractive status, or require the removal of lenses during the day".
  • A known allergy to fluorescein, benoxinate, proparacaine, or cyclopentolate.
  • A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections.
  • Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction.
  • Known ocular or systemic disease such as, but not limited to: anterior uveitis or iritis, episcleritis or scleritis, glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, or diabetes.
  • At the discretion of the Investigator, any ocular, systemic or neuro developmental conditions that could influence refractive development such as, but not limited to: persistent pupillary membrane, vitreous hemorrhage, cataract, corneal scarring, ptosis, eyelid hemangiomas, Marfan's syndrome, Down syndrome, Ehlers-Danlos syndrome, Stickler syndrome, ocular albinism, retinopathy of prematurity. Subjects with trichiasis, that in the Investigator's judgement does not interfere with contact lens wear, are eligible for this study.
  • Keratoconus or an irregular cornea.
  • Subjects with any Grade 2 or greater finding during the slit lamp examination, or subjects with any scar or neovascularization within the central 6 mm of the cornea, or subjects with corneal infiltrates, of ANY GRADE.
  • Subjects with any "present" finding during the slit lamp examination (biomicroscopy) that, in the investigator's judgment, interferes with contact lens wear. Subjects with minor peripheral corneal scarring (that does not extend into the central area), that in the Investigator's judgment does not interfere with contact lens wear, are eligible for this study.
  • The Investigator for any reason considers that it is not in the best interest of the Subject to participate in the study.
  • Subjects participating in any drug clinical investigation within 4 weeks or device clinical investigation within 2 weeks prior to entry into this study (Screening/Dispensing Visit) and/or planning to do so during the period of study participation.
  • Immediate family or close relative is a member of site study team members

结局指标

主要结局

Mean change from baseline in axial length.

时间窗: 1 and 2 years

Mean change from baseline in axial length will be evaluated at the one-year and two-year visits.

Mean change from baseline in cycloplegic SERE.

时间窗: 1 and 2 years

Mean change from baseline in cycloplegic SERE will be evaluated at the one-year and two-year visits.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验